ALLMedicine™ Pheochromocytoma Center
Research & Reviews 1,613 results
https://doi.org/10.1007/s12020-022-03073-0 10.1089/thy.2014.0335 10.1016/j.beem.2019.04.008 10.1530/EJE-21-0753 10.1056/NEJMoa012915 10.1002/humu.23430 10.1210/jc.2012-3192 10.1111/cen.13386 10.1002/bjs.10746 10.1677/ERC-10-0211 10.1067/msy.2001.118373 10.1007/978-3-642-84749-3_9 10.1016/j.surg.2003.08.005 10.1016/j.jamcollsurg.2003.12.001 10.1016/j.jamcollsurg.2012.10.012 10.1080/01621459.1958.10501452 10.1038/bjc.1977.1 10.1016/S1470-2045(14)70154-8 10.1001/jamanetworkopen.2019.8898 10.1001/jama.1996.03540190047028 10.1111/cen.12978 10.1002/1096-9896(2000)9999:9999<::AID-PATH679>3.0.CO;2-B
Endocrine Machens A, Lorenz K et. al.
May 18th, 2022 - The objective of this study was to provide RET genotype-specific data on recurrent ipsilateral pheochromocytoma in multiple endocrine neoplasia type 2A (MEN2A), which are sparse. Kaplan-Meier analyses were performed to determine the risk of recurr...
https://doi.org/10.1002/jso.26918
Journal of Surgical Oncology; Isiktas G, Nazli Avci S et. al.
May 15th, 2022 - Pheochromocytoma is a challenging tumor type requiring resection with a clear margin and an intact capsule to prevent recurrences. Our aim was to compare perioperative outcomes of laparoscopic adrenalectomy (LA) versus robotic adrenalectomy (RA) f...
https://clinicaltrials.gov/ct2/show/NCT00004847
May 13th, 2022 - Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare and clinically important chromaffin cell tumors that typically arise from the adrenal gland or from extra-adrenal paraganglia, respectively. The clinical features and consequences of PHE...
https://clinicaltrials.gov/ct2/show/NCT03206060
May 13th, 2022 - Background: Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare tumors arising from neural crest tissue that can develop in sympathetic and parasympathetic paraganglia throughout the body. Those arising in the adrenal gland are called PHEOs whi...
https://clinicaltrials.gov/ct2/show/NCT04770831
May 12th, 2022 - This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumo...
Guidelines 4 results
https://doi.org/10.1097/MPA.0000000000001792
Pancreas Fishbein L, Del Rivero J et. al.
May 4th, 2021 - This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management and surveillance of metastatic and unresectable pheochromocytoma and paraganglioma held on October 2 and 3, 2019. The p...
https://doi.org/10.1038/gim.2018.28
Genetics in Medicine : Official Journal of the American C... Stewart DR, Korf BR et. al.
Jul 15th, 2018 - This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessaril...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.
Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419007
Pancreas Chen H, Sippel RS et. al.
Jul 29th, 2010 - Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic para...
Drugs 49 results see all →
Clinicaltrials.gov 34 results
https://clinicaltrials.gov/ct2/show/NCT03206060
May 13th, 2022 - Background: Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare tumors arising from neural crest tissue that can develop in sympathetic and parasympathetic paraganglia throughout the body. Those arising in the adrenal gland are called PHEOs whi...
https://clinicaltrials.gov/ct2/show/NCT00004847
May 13th, 2022 - Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare and clinically important chromaffin cell tumors that typically arise from the adrenal gland or from extra-adrenal paraganglia, respectively. The clinical features and consequences of PHE...
https://clinicaltrials.gov/ct2/show/NCT04770831
May 12th, 2022 - This is an observational, single institution study designed to determine the benefit of 131I-MIBG therapy in subjects with refractory, relapsed or progressive neuroblastoma, malignant pheochromocytoma or paraganglioma, or other neuroendocrine tumo...
https://clinicaltrials.gov/ct2/show/NCT03015844
Apr 12th, 2022 - This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible f...
https://clinicaltrials.gov/ct2/show/NCT05082311
Feb 10th, 2022 - The aim of this research is to study the cardiac and vascular changes in Pheochromocytoma/ Paraganglioma patients and their reversal following curative surgery This prospective, case-control study is conducted at SGPGIMS, Lucknow, India, tertiary ...
News 65 results
https://www.onclive.com/view/car-t-cell-therapy-may-represent-a-new-option-in-medullary-thyroid-cancer
May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...
https://www.mdedge.com/fedprac/article/249919/nephrology/pheochromocytoma-incidental-finding-asymptomatic-older-adult-renal
Maryam Bushra Ahmed, Zayan Ahmed Sami et. al.
Dec 15th, 2021 - Pheochromocytoma is a rare catecholamine-secreting tumor of chromaffin cells of the adrenal medulla or sympathetic ganglia, occurring in about 0. 2 to 0.
https://www.onclive.com/view/influx-of-therapies-in-nets-prompts-questions-over-combinations-and-sequencing
Nov 19th, 2021 - Tyrosine kinase inhibitors (TKIs), hypoxia-inducible factor 2α (HIF-2α) inhibitors, and peptide receptor radiotherapy are generating excitement in the field of neuroendocrine tumors (NETs), explained Diane Reidy-Lagunes, MD. However, until more de...
https://www.mdedge.com/internalmedicine/article/248875/geriatrics/case-older-patient-t2d-has-recurrent-flushing
Douglas S. Paauw, MD
Nov 18th, 2021 - A 64 year-old man with type 2 diabetes complains of recurrent flushing for the past 6 months. He has had no other symptoms.
https://www.medscape.com/viewarticle/959868
Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...